乙型肝炎病毒基因变异和耐药与临床肝病的关系

蒋自卫; 史文高

乙型肝炎病毒基因变异和耐药与临床肝病的关系

东南大学附属南京市第二医院肝病研究室

详细信息

中图分类号: R512.62
计量
- 文章访问数: 3163
- HTML全文浏览量: 3
- PDF下载量: 860
- 被引次数: 0
出版历程
- 出版日期: 2010-04-20

Relationship between gene variation and drug resistance of hepatitis B virus and clinical liver disease

摘要

HTML全文

参考文献(22)

[1]Tanaka Y, Mukaide M, Orito E, et al.Specific mutations in en-hancer II/core promoter of hepatitis B virus subgenotypes C1/C2 in-crease the risk of hepatocellular carcinoma[J].J Hepatol, 2006, 45 (5) ∶646-653.

[2]Chu CM, Yeh CT, Lee CS, et al.Precore stop mutation HBeAgpositive patients with chronic hepatitis B:clinical charactcristics andcorrelation with the course of HBeAg-to-anti-HBe seroconversion[J].J Clin Micrnhiol, 2002, 40 (1) ∶16-21.

[3]谢琴秀, 许家璋, 李平, 等.江苏地区乙型肝炎病毒基因分型及其临床意义[J].疾病控制杂志, 2005, 9 (2) ∶171-173.

[4]Truong BX, Seo Y, Yano Y, et al.Genotype and variations in corepromoter and pre-core regions are related to progression of disease inHBV infected patients from Northern Vietnam[J].Int J Mol Med, 2007, 19 (2) ∶293-299.

[5]Tong MJ, Blatt LB, Kao JH, et al.Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface an-tigen positive hepatocellular carcinoma:a comparison with chroniccarriers[J].Liver Int, 2007, 27 (10) ∶1356-1363.

[6]Yoo BC, Park JW, KimHJ, et al.Precore and core promoter muta-tions of hepatitis B virus and hepatitis B e antigen negative chronichepatitis B in Korea[J].J Hepatol, 2003, 38 (1) ∶98-103.

[7]Yuan J, Zhou BP, Tanaka Y, et al.Hepatitis B virus (HBV) gen-otypes/subgenotypes in China:mutations in core promoter and pre-core/core and their clinical implications[J].J Clin Virol, 2007, 39 (2) ∶87-93.

[8]Wu L, He JW, Yao X, et al.A novel hepatitis B virus variant S129 (Gln—>Leu) :lack of correlation between antigenicity andimmunogenicity[J].J Med Virol, 1999, 59 (4) ∶424-430.

[9]Cao Z, Bai X, Guo X, et al.High prevalence of hepatitis B viruspre S mutation and its association with hepatocellular carcinoma inQidong, China[J].Arch Virol, 2008, 153 (10) ∶1807-1812.

[10]Chen BF, Liu CJ, JowGM, et al.High Prevalence and Mapping ofPre S Deletion in Hepatitis B Virus Carriers With Progressive LiverDiseases[J].Gastroenterology, 2006, 130 (4) ∶1153-1168.

[11]Chen CH, Hung CH, Lee CM, et al.Pre S deletion and complexmutations of hepatitis B virus related to advanced liver disease inHBeAg negative patients[J].Gastroenterology, 2007, 133 (5) ∶1466-1474.

[12]Chen CH, Lee CM, Lu SN, et al.Clinical significance of hepatitisB virus (HBV) genotypes and precore and core promoter mutationsaffecting HBV e antigen expression in Taiwan[J].J Clin Microbi-ol, 2005, 43 (12) ∶6000-6006.

[13]Laras A, Koskinas J, Hadziyannis SJ.In vivo suppression of pre-core mRNA synthesis is associated with mutations in the hepatitis Bvirus core promoter[J].Virology, 2002, 295 (1) ∶86-96.

[14]Jang JW, Lee YC, Kim MS, et al.A13 year longitudinal study ofthe impact of double mutations in the core promoter region of hepati-tis B virus on HBeAg seroconversion and disease progression in pa-tients with genotype C chronic active hepatitis[J].J Viral Hepat, 2007, 14 (3) ∶169-175.

[15]Ferns RB, Naoumov NV, Gilson RJ, et al.Presence of hepatitis Bvirus core promoter mutations pre seroconversion predict persistentviral replication after HBeAg loss[J].J Clin Virol, 2007, 39 (3) ∶199-204.

[16]Kuang SY, Jackson PE, Wang JB, et al.Specific mutations of hep-atitis B virus in plasma predict liver cancer development[J].ProcNatl Acad Sci USA, 2004, 101 (10) ∶3575-3580.

[17]Sakugawa H, Nakasone H, Nakayoshi T, et al.Preponderance ofheatitis B virus genotype B contributes to a better prognosis of chron-ic HBV infection in Okinawa[J].Japan J Med Virol, 2002, 67 (4) ∶484-489.

[18]Degertekin B, Lok AS.Monitoring antiviral resistance in patientsreceiving nucleus tide analog therapies for hepatitis B:which meth-od should be used?[J].J Hepatol, 2008, 48 (6) ∶892-894.

[19]Liaw YF, Leung NW, Chang TT, et al.Effects of extended lamivu-dine therapy in Asian patients with chronic hepatitis B[J].Gastroenterology, 2000, 119 (1) ∶172-180.

[20]Leung NW, Lao CL, Chang IR, et al.Extended lamivudine treat-ment in patients with chronic hepatitis B enhances hepatitis B e an-tigen seroconversion rates:results after 3 years of therapy[J].Hepatology, 2001, 33 (6) ∶1527-1532.

[21]Chen CH, Lee CM, Lu SN, et al.Comparison of sequence changesof precore and core promoter regions in HBeAg positive chronic hep-atitis B patients with and without HBeAg clearance in lamivudinetherapy[J].J Hepatol, 2006, 44 (1) ∶76-82.

[22]Angus P, Vaughan R, Xiong S, et al.Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in theHBV polymerase[J].Gastroenterology, 2003, 125 (2) ∶292-297.

施引文献

资源附件(0)

访问统计